Relmada Therapeutics (RLMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.11
- Estimate
- -$0.20
- Surprise
- +44.4%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Relmada Therapeutics (RLMD) reported a narrower loss than forecast — diluted EPS of -$0.11 against the -$0.20 estimate (a 44.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RLMD Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +44.4% surprise compares with a -199.9% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: drug candidates
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (17 sells, 3.94% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.63
- Price target
- $11.02
- Stop
- $4.31
- Upside to target
- +138.0%
- Reward-to-risk
- 11.7:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
RLMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $493.9M
- P/E (fwd)
- -8.3
- 52-week range
- $0.59–$8.00
- Off 52-week high
- 42.1%
- RSI (14)
- 32
- Volume vs avg
- 0.80×
- Score today
- 5.4/10